Subscribe to Updates for Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Participants With Traumatic Brain Injury

Stay informed about the latest developments in this trial. By subscribing, you will receive updates directly to your email. These updates will provide you with important information regarding any changes or progress related to the trial.

1/3

Tell us a little bit about yourself:

Fields marked with asterisk (*) are mandatory.

People in the crowd
© 2026 Otsuka America Pharmaceutical,
Inc All rights reserved.

January  2026 01US26EUC0016